Chronic Myeloid Leukemia: A Review

医学 达沙替尼 尼罗替尼 伊马替尼 博舒替尼 费城染色体 髓系白血病 甲磺酸伊马替尼 内科学 白血病 人口 慢性粒细胞白血病 肿瘤科 免疫学 染色体易位 生物化学 化学 基因 环境卫生
作者
Elias Joseph Jabbour,Hagop M. Kantarjian
出处
期刊:JAMA [American Medical Association]
卷期号:333 (18): 1618-1618 被引量:142
标识
DOI:10.1001/jama.2025.0220
摘要

Importance: Chronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML. Observations: Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, which is defined by the BCR::ABL1 oncogene that develops after fusion of the ABL1 proto-oncogene to the constitutively active BCR gene. Approximately 90% of people with CML present with an indolent chronic phase of CML, defined as blasts of less than 10% in the blood or bone marrow, absence of extramedullary evidence of leukemia, basophils of less than 20%, and platelet counts of 100 to 1000 × 109/L. The most advanced stage is CML blastic phase (CML-BP), characterized by the World Health Organization as 20% or more blasts/immature cells and by the MD Anderson Cancer Center and European LeukemiaNet as 30% or more. Approximately 1% to 2% of patients with CML present with CML-BP. Since 2000, first-generation tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1, such as imatinib, and second-generation TKIs, such as bosutinib, dasatinib, and nilotinib, have improved CML-related mortality from 10% to 20% per year to 1% to 2% per year, such that patients with CML have survival rates similar to those of a general age-matched population. Six BCR::ABL1 TKIs have been approved by the US Food and Drug Administration, including 5 that are first-line treatment (imatinib, dasatinib, bosutinib, nilotinib, and asciminib) and 5 approved for treatment after disease progression despite initial therapy (dasatinib, bosutinib, nilotinib, ponatinib, asciminib). Effects on improved survival are similar with all TKIs, although more patients are able to promptly achieve and maintain BCR::ABL1 clearance with second- and third-generation TKIs. Medication adherence is important to maintain treatment responsiveness. All TKIs are associated with hematologic toxicity, such as myelosuppression, with additional agent-specific adverse effects, such as pleural effusion (dasatinib), arterio-occlusive events such as myocardial infarction, stroke, and peripheral artery disease (nilotinib, ponatinib), gastrointestinal disturbance (bosutinib), or increased amylase and lipase with pancreatitis (ponatinib, asciminib, nilotinib). These adverse effects should be considered when selecting a TKI. Allogeneic hematopoietic stem cell transplant is a reasonably safe therapy, with cure rates ranging from 20% to 60% based on the stage of CML at the time of transplant. Stem cell transplant is reserved for patients with CML who do not respond to second-generation TKIs, those with intolerance to multiple TKIs, or those with accelerated-phase CML or CML-BP. Conclusions and Relevance: Chronic myeloid leukemia is a myeloproliferative neoplasm that can typically be effectively treated with TKIs, improving survival similar to that of a general age-matched population. Many patients require continuous TKI therapy. Therefore, TKI therapy should be selected with consideration of adverse effects, and patients should be helped to maximize adherence to TKI treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蟹寒樂发布了新的文献求助10
刚刚
刚刚
can发布了新的文献求助10
刚刚
刚刚
合适的白筠完成签到,获得积分10
1秒前
搜集达人的应助被去向未来采纳,获得20
1秒前
2秒前
2秒前
llll发布了新的文献求助10
2秒前
3秒前
4秒前
888发布了新的文献求助10
4秒前
211完成签到,获得积分20
5秒前
SciGPT的应助被小周爱学术采纳,获得10
6秒前
7秒前
石头完成签到,获得积分10
7秒前
TUOUO完成签到,获得积分10
7秒前
无所事事完成签到,获得积分10
8秒前
wyc发布了新的文献求助10
8秒前
unforgettable发布了新的文献求助10
8秒前
8秒前
zyl666关注了科研通微信公众号
8秒前
9秒前
王永明完成签到,获得积分10
9秒前
orixero的应助被888采纳,获得10
9秒前
迷路牛青发布了新的文献求助10
9秒前
谭霸天完成签到,获得积分10
10秒前
10秒前
传奇3的应助被tooty采纳,获得10
11秒前
11秒前
十三完成签到,获得积分10
11秒前
11秒前
白nb66完成签到 ,获得积分10
13秒前
科目三的应助被夏以宁采纳,获得10
13秒前
郑睿涛发布了新的文献求助10
13秒前
ViVi水泥要干喽完成签到 ,获得积分10
13秒前
天地一体发布了新的文献求助10
14秒前
14秒前
核桃发布了新的文献求助10
14秒前
FashionBoy的应助被腼腆的水蓝采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648